Invion

Invion PP&E per Employee

The PP&E per Employee of Invion (IVX.AX) as of Oct 29, 2026 is 7,310.38 AUD. In the previous year, PP&E per Employee was 59.88 AUD — a change of 12,109.39% (higher).

PP&E per Employee

7,310.38AUD

YoY

12,109.39%

Last updated:

PP&E per Employee of Invion is 2023 7,310.38 AUD. PP&E per Employee of Invion was 2022 59.88 AUD. It decreases by 12,109.39% higher compared to the previous year.

The Invion PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2015
3,340.38 AUD
Jan 1, 2016
722.75 AUD
Jan 1, 2017
329.75 AUD
Jan 1, 2019
602.38 AUD
Jan 1, 2020
486.38 AUD
Jan 1, 2021
128.00 AUD
Jan 1, 2022
59.88 AUD
Jan 1, 2023
7,310.38 AUD
The Invion PP&E per Employee history
YEARPP&E per EmployeeYoY
7,310.38AUD+12,109.39%
59.88AUD-53.22%
128.00AUD-73.68%
486.38AUD-19.26%
602.38AUD+82.68%
329.75AUD-54.38%
722.75AUD-78.36%
3,340.38AUD-7.85%
3,625.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

PP&E per Employee of Invion is 7,310.38 AUD in 2023.

PP&E per Employee of Invion changed from 59.88 AUD to 7,310.38 AUD, representing a 12,109.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Invion since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Invion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Invion

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Invion